



***PANK1* associates with cancer metabolism and immune infiltration in clear cell renal cell carcinoma: a retrospective prognostic study based on the TCGA database**

Bin Wang^{1,2#}, Bin Liu^{3#}, Qing Luo¹, Ding Sun¹, Hao Li¹, Jie Zhang¹, Xinye Jin¹, Xiaowei Cheng¹, Jingxue Niu¹, Qing Yuan⁴, Yizhi Chen^{1,2}

¹Department of Nephrology, Hainan Hospital of Chinese PLA General Hospital, The Hainan Academician Team Innovation Center, Sanya, China;

²Senior Department of Nephrology, The First Medical Center of Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing, China; ³Department of Nephrology and Rheumatology, Hainan Provincial Hospital of Traditional Chinese Medicine, Haikou, China;

⁴Senior Department of Urology, The Third Medical Center of Chinese PLA General Hospital, Beijing, China

Contributions: (I) Conception and design: B Wang, B Liu, Q Yuan, Y Chen; (II) Administrative support: Y Chen, Q Yuan; (III) Provision of study materials or patients: B Wang, B Liu, Q Luo, D Sun, H Li, J Zhang, X Jin, X Cheng, J Niu; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

#These authors contributed equally to this work.

Correspondence to: Yizhi Chen. Department of Nephrology, Hainan Hospital of Chinese PLA General Hospital, Sanya 572013, China.

Email: yizchen@126.com; Qing Yuan. Senior Department of Urology, The Third Medical Center of Chinese PLA General Hospital, Beijing, China.

Email: qyuanmd@outlook.com.

Background: Identify key biomarkers to improve the clinical prognosis of patients with advanced and metastatic clear cell renal cell carcinoma (ccRCC) remains an important research topic. Recently, ccRCC has been regarded as a metabolic disease. Pantothenate kinase-1 (*PANK1*) has been shown to play an important regulatory role in global metabolism and associates with the pathogenesis of hepatocellular carcinoma. Therefore, we aimed to investigate the role of *PANK1* in the prognosis of ccRCC and in metabolism and immunity.

Methods: *PANK1* messenger ribonucleic acid (RNA) expression patterns in ccRCC using The Cancer Genome Atlas (TCGA) database. The clinical prognostic significance of *PANK1* in ccRCC and a Cox regression was performed to evaluate the clinical factors associated with prognosis with confounding factors adjusted. The signaling pathways related to *PANK1* expression were identified by Gene Ontology (GO) investigation and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. The Tumor Immune Estimation Resource database was used to analyze the correlation between *PANK1* and tumor-infiltrating immune cells.

Results: A total of 539 ccRCC patients and corresponding clinical samples and data from TCGA were included in this analysis. Significant differences were observed in *PANK1* expression levels between tumor tissues and adjacent normal tissues in both TCGA-Kidney Renal Clear Cell Carcinoma cohort (4.40 *vs.* 2.94, $P < 0.001$). *PANK1* expression was found to be correlated with pathological stage, histological grade, age, sex, and clinical prognosis. Specifically, the low expression of *PANK1* was found to be closely related to poor overall survival (OS), disease-specific survival (DSS), and the progression-free survival (PFS) in ccRCC patients. The receiver operating characteristic curve suggested that *PANK1* could be a potential prognostic biomarker (area under the curve = 0.880), and that the promoter methylation levels of *PANK1* were correlated with clinical factors. Further, *PANK1* expression was found to be associated with multiple immune cell types and correlated with the enrichment of these cells. Finally, we further investigated the role of *PANK1* in tumor growth and mitochondrial metabolism using ccRCC cells.

Conclusions: *PANK1* correlates with ccRCC prognosis, tumor immune status and metabolism using the TCGA data. *PANK1* might be a prognostic marker of clinical prognosis for ccRCC patients.

Keywords: Clear cell renal cell carcinoma (ccRCC); pantothenate kinase-1; immune infiltration; promoter methylation; tumor metabolism

Submitted May 13, 2022. Accepted for publication Jul 04, 2022.

doi: 10.21037/tcr-22-1488

View this article at: <https://dx.doi.org/10.21037/tcr-22-1488>

Introduction

Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal cell carcinoma and accounts for nearly 75% of all cases (1). For early stage ccRCC, surgical excision is the best treatment approach. However, despite substantial advances in ccRCC-targeted therapies, such as tyrosine kinase or mammalian target of rapamycin (mTOR) inhibitors, the clinical prognosis of patients with advanced and metastatic ccRCC remains unsatisfactory (2). Additionally, ccRCC is reported to be a highly immune-infiltrated tumor, and immunotherapy-based combination therapeutics have been shown to have increased clinical benefits in terms of their efficacy and the overall survival (OS) of patients with metastatic RCC (3,4). Recently, the general metabolism mitochondrial functions of RCC were reported to be correlated with clinical prognosis (5,6); however, the mechanisms of this correlation are not clear. Thus, investigating the mechanisms that link metabolism and immune infiltration is important for the pathogenesis and treatment of ccRCC.

Previous studies concentrate on the biological and clinical markers associated with the prognosis of ccRCC (7). Petitprez *et al.* reviewed a total of 341 distinct markers and 13 multiple-marker models for ccRCC, of which the main ones are distributed in cell cycle, angiogenesis, hypoxia, and immune response (8). Recent study indicates that ccRCC is regarded as a metabolic disease (9). However, still few study concentrated on the metabolic markers and clinical prognosis of ccRCC (10). Therefore, identifying the key metabolic markers associated with the clinical prognosis of ccRCC is important for further understanding of ccRCC.

Pantothenate kinase-1 (*PANK1*) is a member of the PanK family, and is involved in the biosynthesis of coenzyme A (CoA) (11). CoA has been shown to be an essential and prevalent cofactor that is essential in more than a hundred diverse metabolic reactions, including the tricarboxylic acid cycle, synthesis of fatty acids and neurotransmitters, activation of immune functions, and repair of connective tissues (12). The PanK family of proteins are responsible for catalyzing the first and rate-limiting step of CoA synthesis

(the phosphorylation of the precursor pantothenate), and thus controlling the cellular content of CoA (13). The CoA levels, which are used to meet the energy demands as an alternative fuel source in tissues, change under metabolic stress. In pathological conditions, increase of intracellular CoA in the liver is required to guarantee the efficient conversion of fatty acids and amino acids in store to energy. Thus, *PANK1* has been shown to play important roles in the metabolism regulation of glucose and lipids, and have promising effects in interventions of metabolism-related disorders (14).

However, little research has been conducted on whether *PANK1* participates in cancer pathogenesis. Zi *et al.* reported that *PANK1* inhibits hepatocellular carcinoma progression by modulating the Wnt/ β -catenin signaling (11). Additionally, *PANK1* has been reported to modulate cell cycle progression via the downregulation of cyclin dependent kinase 6 and p130 proteins (15). A recent bioinformatic analysis revealed that *PANK1* is an important differentially expressed gene between normal and tumor tissues (16); however, the role of *PANK1* in ccRCC has not yet been systematically investigated, especially its role in the metabolic regulation and clinical prognosis. In this study, we used data from The Cancer Genome Atlas-Kidney Renal Clear Cell Carcinoma (TCGA-KIRC) cohort to study the correlations between *PANK1* expression and the clinical prognosis of ccRCC patients. The effects of *PANK1* on cell viability and cell metabolism were also detected using ccRCC cell lines. Our data revealed the important role of *PANK1* in ccRCC and its relationship to tumor metabolism and immunity. We present the following article in accordance with the TRIPOD reporting checklist (available at <https://tcr.amegroups.com/article/view/10.21037/tcr-22-1488/rc>).

Methods

Study design and research procedures

This study is a retrospective prognostic study analyzing the expression difference of *PANK1* between tumor and adjacent normal tissues, correlations with the clinical factors, overall

and disease-specific survival analyses using the TCGA-KIRC data. Moreover, receiver operator characteristic curve (ROC), time-dependent ROC and nomogram model incorporating key clinical factors and *PANK1* expression patterns were built. In addition, promoter methylation status of *PANK1* and the correlations with key clinical factors were investigated. Then, signaling pathways and functional protein networks were clustered, while the associations between *PANK1* expression, immune cell infiltrations were presented. At last, *in vitro* cell experiments were conducted to further validate the results from the clinical analyses. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Gene expression profile analysis

PANK1 messenger ribonucleic acid (mRNA) levels in several cancer types were analyzed using the Tumor Immune Estimation Resource (TIMER) database, which is based on data from TCGA (17). The TCGA-KIRC cohort comprised a total of 539 tumor and 72 adjacent normal tissue samples from ccRCC patients, and all the clinical information. The *PANK1* mRNA expression levels in the tumor tissues and normal tissues from paired and unpaired patients in TCGA database were compared. Additionally, 2 Gene Expression Omnibus (GEO) data sets (<https://www.ncbi.nlm.nih.gov/geo/>) were used to analyze *PANK1* expression patterns.

Correlation analysis of PANK1 expression and clinical characteristics

Correlation analyses of *PANK1* mRNA expression and clinicopathological characteristics, including tumor (T) stage, node (N) stage, metastasis (M) status, pathological stage, histological grade, sex, and age, were performed in TCGA-KIRC cohort with R software using the “ggplot2” package. Meanwhile, the confounding effects of clinical factors were adjusted to ascertain the independent prognostic role of *PANK1*. Additionally, the expression levels of *PANK1* in patients with different clinical stages from TCGA-KIRC cohort were calculated using the University of Alabama Cancer Database (UALCAN) website.

Overall and disease-specific survival analyses

The Gene Expression Profiling Interactive Analysis (GEPIA) website (available at <http://gepia.cancer-pku.cn/>) is a scientific tool to analyze clinical data from TCGA database and tissue-specific expression patterns (18). The online Kaplan-Meier plotter (available at <http://kmplot.com/analysis/>) can assess the role of individual genes on the survival prognosis of patients with cancer. The prognostic value of *PANK1* expression in ccRCC patients was assessed using data from TCGA-KIRC cohort. OS, disease-specific survival (DSS), and progression-free survival (PFS) were determined by classifying the patients into 2 categories according to their median *PANK1* expression level (high versus low). Log-rank P values and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. A ROC curve of diagnosis, a time-dependent ROC curve, and a nomogram model for prognosis analysis were created using the “pROC”, “timeROC”, and “survival” packages in R, respectively. The threshold value of area under curve (AUC) for a good prognosis predicting model is 0.75 according to previous study (19). All the clinical data used in this section were obtained from TCGA database.

PANK1 messenger ribonucleic acid (mRNA) levels in several cancer types were analyzed using the Tumor Immune Estimation Resource (TIMER) database, which is based on data from TCGA (17). The TCGA-KIRC cohort comprised a total of 539 tumor and 72 adjacent normal tissue samples from ccRCC patients, and all the clinical information. The *PANK1* mRNA expression levels in the tumor tissues and normal tissues from paired and unpaired patients in TCGA database were compared. Additionally, 2 Gene Expression Omnibus (GEO) data sets (<https://www.ncbi.nlm.nih.gov/geo/>) were used to analyze *PANK1* expression patterns.

Profiling of genes co-expressed with PANK1 and KEGG/GO analyses

The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genome (KEGG) analyses were performed using the co-expressed genes with the “clusterProfiler” package in R to explore the possible functions and signaling pathways affected by *PANK1*. The co-expression genes were screened using “limma” in R (20). The GO analysis included the biological process (BP), cellular composition (CC), and molecular function (MF); a two-sided P value <0.05 was considered statistically significant (21). A functional protein association network of *PANK1* in *Homo sapiens* was generated by the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) to display the protein-protein interaction networks (22).

Methylation analysis of PANK1 in ccRCC

An analysis of *PANK1* promoter methylation status and clinical characteristics, including sample type, individual cancer stage, histological grade, sex, and age, was performed in the UALCAN database. Additionally, the online MethSurv tool was used to analyze the role of different methylation sites of *PANK1* promoter with the survival data in TCGA cohort of ccRCC using the deoxyribonucleic acid (DNA) methylation data (23). Specifically, patients with ccRCC were divided into high- and low-risk groups

according to the median methylation value of *PANK1*. The Xena platform was also used to analyze the correlation between the *PANK1* expression and the methylation levels of certain methylation sites (24).

Correlation analysis of PANK1 and immune-infiltrating cells

The TIMER database was employed to analyze the levels and clinical significance of tumor-infiltrating immune cells (25), including cluster of differentiation (CD) 8⁺ T cells, CD4⁺ T cells, B cells, macrophages, neutrophils, and dendritic cells (DCs), and the relationship between these cell types and *PANK1* expression was determined. The CIBERSORT (<https://cibersort.stanford.edu/>) (26) database was used to further quantify the infiltrating proportion of immune cells in ccRCC samples with high and low *PANK1* expression. The “ggplot2,” “tidyverse,” and “reshape2” packages in R were used for the data analyses and graph plotting.

Cell culture, transfection, and cell viability assays

The ccRCC cell lines 786-O and CaKi-2 cells were obtained from the National Collection of Authenticated Cell Cultures (Shanghai, China) and cultured in Dulbecco's modified Eagle's medium containing fetal bovine serum at a final concentration of 10% in a humidified atmosphere of 5% carbon dioxide. Small-interfering RNAs (siRNAs) against *PANK1* and control siRNAs (scrambled siRNAs) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Lipofectamine 3000 transfection reagent (Thermo Fisher Scientific, Waltham, MA, USA) was used in accordance with the manufacturer's instructions. After transfection, Cell Counting Kit-8 (CCK-8) assays were performed as previously described (27).

Mitochondrial function measurements

The oxygen consumption rate (OCR) was analyzed using a 2-channel titration injection respirometer (Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria) equipped with 2 chambers, as previously described (28). Additionally, mitoSOX Red (ThermoFisher) was used to determine mitochondrial-specific reactive oxygen species (ROS) production. To quantify the intensity of MitoSOX fluorescence, the plates were measured using a Fluoroskan Ascent Fluorometer (ThermoFisher, Helsinki, Finland).

Statistical analysis

SPSS (version 20.0) and R project (version 4.0.4) software were used for the statistical analyses. The clinical data are presented as the mean \pm standard deviation (SD), while the cell experimental data are presented as the mean \pm standard error mean (SEM). Independent samples t-tests and paired samples t-tests were performed to analyze differences in *PANK1* mRNA levels between the tumor tissues and the adjacent normal tissues of ccRCC patients from the TCGA and GEO databases. The chi-squared test was used to analyze the associations between *PANK1* expression levels and the clinical characteristic variables using TCGA data. Univariate and multivariate analyses were performed using the Cox proportional hazards regression model. For the details of multivariate Cox regression analysis, all the candidate clinical factors available in TCGA cohort were analyzed using the univariate cox analysis. The clinical factors with significant significance were included in the multivariate analyses with adjustments of confounding factors. The factors entered the multivariate Cox analysis model were considered as the outcome variables. OS, DSS, and PFS analyses were performed using Kaplan-Meier plots, and the differences were compared using the log-rank test. Gene expression associations were determined by a Spearman correlation analysis. Differences were considered statistically significant when the two-sided P value was <0.05.

Results

PANK1 expression is more decreased in ccRCC tissues than normal tissues

To further evaluate the *PANK1* expression profiles in human tumors, we analyzed the TIMER database. *PANK1* expression was more decreased in cholangiocarcinoma, colon adenocarcinoma, glioblastoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, head and neck squamous cell carcinoma, liver hepatocellular carcinoma, prostate adenocarcinoma, and thyroid carcinoma tissues than normal tissues (see *Figure 1A*). Thus, we focused on the role of *PANK1* in renal cancers. More specifically, in TCGA-KIRC cohort, which comprised a total of 539 tumor samples and 72 adjacent normal samples, the expression of *PANK1* was decreased in the KIRC tissues in both the unpaired and paired data ($P < 0.001$; see *Figure 1B*). Further, the expression patterns of *PANK1* were verified using GEO data sets GSE100666 (N=3 in each group) and GSE66270 (N=14 in each group), and the results revealed




Figure 1 Dysregulated *PANK1* expression patterns between tumor and adjacent tissues of ccRCC. (A) The *PANK1* expression levels in the pan-cancer tissues and normal tissues (TCGA cancer expression compared to TCGA normal expression), * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. (B) The *PANK1* expression levels in the unpaired ($N = 72$ in normal group and $N = 539$ in tumor group) and paired ($N = 72$) patients from the TCGA-KIRC cohort. *** $P < 0.001$. (C and D) The *PANK1* expression patterns of the samples from GSE100666 ($N = 3$ per group) and GSE66270 ($N = 14$ per group) data sets. * $P < 0.05$, *** $P < 0.001$. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangio carcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, Sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma; TPM, transcripts per million.

that *PANK1* expression was decreased in the tumor tissues than the normal control tissues (see *Figure 1C, 1D*).

***PANK1* expression is correlated with the clinical prognosis of ccRCC patients**

According to the TCGA-KIRC data, patients with ccRCC in TCGA-KIRC cohort were divided into high ($N = 270$) and low *PANK1* ($N = 269$) groups according to both our analysis and previous preprint (29). It showed that *PANK1* expression

levels were correlated with the key clinical characteristics. Next, the expression patterns of *PANK1* at different clinical stages were analyzed in TCGA-KIRC cohort. Our results showed that *PANK1* expression decreased as the T stage increased, and that there were significant differences between patients with stages T1 and T3 ($P < 0.001$), and stages T1 and T4 ($P < 0.05$; see *Figure 2A*). Additionally, N1-stage patients had lower *PANK1* expression levels than N0-stage patients ($P < 0.05$), and M1-stage patients also had lower *PANK1* expression levels than M0-stage patients ($P < 0.01$) (see




Figure 2 Relationship between the expression of *PANK1* and clinical parameters of ccRCC from the TCGA-KIRC cohort. The expression patterns of *PANK1* were correlated with (A) T stages, (B) N stages, (C) M stages, (D) pathologic stages, (E) histologic grades, (F) gender, (G) age, (H) OS, (I) DSS, and (J) the PFI. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, ns, not significant. TPM, transcripts per million; TCGA, The Cancer Genome Atlas; KIRC, Kidney Renal Clear Cell Carcinoma; OS, overall survival; DSS, disease-specific survival; PFI, progression-free interval.

Figure 2B,2C). Regarding pathological stage and histological grade, patients with a higher stage or grade had decreased *PANK1* levels compared to those with a lower stage or grade (see Figure 2D,2E). Male patients had decreased *PANK1* levels, but no significant differences were observed between older (>60 years) and younger (<60 years) patients (see Figure 2F,2G). Further, dead patients had decreased *PANK1* levels compared to alive patients according to the OS, DSS, and progression-free interval (PFI) outcomes (see Figure 2H-2J). Univariate Cox analysis indicated that key clinical characteristics exhibited a significant correlation with clinical prognosis according to previous study (30). Patients with low *PANK1* expression increased mortality compared with high

PANK1 patients [hazards ratio (HR) = 2.702, 95% confidence interval 1.957 to 3.731]; however, only M stage, histological stage, age, and *PANK1* expression level were included in the multivariate analysis after adjusting for the confounding effects of clinical factors (see Table 1). These results indicate that *PANK1* expression plays an important role in modulating clinical prognosis.

***PANK1* is an independent protective prognostic factor in ccRCC patients**

The prognostic value of *PANK1* expression in patients with ccRCC was assessed by Kaplan-Meier plots and

Table 1 The multivariate cox analyses of key clinical characteristics in ccRCC

Characteristics	Total (N)	Multivariate analysis	
		HR (95% CI)	P value
T stage	539		
T1 & T2	349	Reference	
T3 & T4	190	1.451 (0.634–3.323)	0.378
N stage	257		
N0	241	Reference	
N1	16	1.312 (0.651–2.646)	0.448
M stage	506		
M0	428	Reference	
M1	78	2.652 (1.567–4.486)	<0.001
Pathologic stage	536		
Stage I & II	331	Reference	
Stage III & IV	205	1.212 (0.479–3.062)	0.685
Histologic grade	531		
G1 & G2	249	Reference	
G3 & G4	282	1.684 (1.020–2.778)	0.041
Age, years	539		
≤60	269	Reference	
>60	270	1.665 (1.086–2.554)	0.019
PANK1	539		
High	270	Reference	
Low	269	2.482 (1.546–3.986)	<0.001

ccRCC, clear cell renal cell carcinoma; HR, hazard ratio; CI, confidence interval; PANK1, pantothenate kinase-1.

Log-rank analyses. Lower *PANK1* levels were associated with significantly shortened OS (HR =0.37, P<0.001; see *Figure 3A*), DSS (HR =0.24, P<0.001; see *Figure 3B*), and PFS (HR =0.36, P<0.001; see *Figure 3C*) in TCGA-KIRC cohort. Thus, our results suggested that *PANK1* is a protective prognostic factor and an independent prognostic marker for ccRCC.

Value of *PANK1* expression in diagnosis and prognosis prediction

The ROC curve showed that *PANK1* expression could be used to accurately differentiate between tumor and

normal tissues (AUC =0.880) (see *Figure 4A*). Additionally, a time-dependent survival ROC curve of *PANK1* was created to predict the 1-, 3-, and 5-year survival rates of patients. However, all these AUC values were lower than 0.6, which suggests that *PANK1* expression cannot be used for clinical prediction (see *Figure 4B*). By integrating the clinicopathological factors (including age, sex, T stage, N stage, M stage, and histological and pathological stages) and *PANK1* expression, a nomogram model was built to predict the survival probabilities at the 1-, 3-, and 5-year for patients in clinical practice. The nomogram model indicated that in addition to M stage, histologic stage, and age, *PANK1* expression is a dominant factor in predicting the survival probability. (see *Figure 4C*).

Associations between *PANK1* methylation status and clinical features in patients with ccRCC

First, we analyzed the promoter methylation levels of *PANK1* and clinical features, and found that ccRCC tumors exhibited increased methylation levels compared to normal tissues (see *Figure 5A*). Additionally, pathological stage 1 had aberrant methylation levels compared to stage 3 or stage 4 (P<0.05) disease (see *Figure 5B*), while histological grade 4 had discrepant methylation levels compared to grade 2 (P<0.01) or stage 3 (P<0.05) disease (see *Figure 5C*). No significant differences in methylation levels were observed between N0 and N1, age, and sex (see *Figure 5D-5F*). Further, the DNA methylation levels of *PANK1* were assessed according to the prognostic value of each single Cytosine-phosphate-Guanine (CpG) using the MethSurv tool. The results of MethSurv suggested a total of 14 methylation CpG sites, among which cg17051995 and cg26739829 had the highest DNA methylation levels (see *Figure 5G*). The methylation levels of 9 CpG sites (i.e., cg06326839, cg09161592, cg09747456, cg12226046, cg17051995, cg18222926, cg19519331, cg20349567, and cg26739829) were found to be correlated with clinical prognosis (P<0.05; see *Table 2*).

GO and KEGG pathway analyses of *PANK1*

The top 100 most positively correlated genes with *PANK1* in the GO and KEGG enrichment analyses were determined by the “clusterProfile” package in R. The GO analysis showed that most of the genes were associated with coenzyme binding, the mitochondrial matrix, peroxisome, and fatty acid catabolism (see *Figure 6A*). The KEGG data suggested that fatty acid metabolism may be related to the




Figure 3 Prognostic value of *PANK1* expression in patients with ccRCC (Kaplan-Meier plotter) from TCGA-KIRC cohort. The OS (A), DSS (B), and PFS (C) survival curves comparing patients with high (red) and low (blue) *PANK1* expression in ccRCC were plotted at the threshold of $P < 0.05$. TCGA, The Cancer Genome Atlas; KIRC, Kidney Renal Clear Cell Carcinoma; ccRCC, clear cell renal cell carcinoma; OS, overall survival; DSS, disease-specific survival; PFS, progression-free survival.




Figure 4 ROC analysis and nomogram model of *PANK1* in ccRCC. (A) The ROC curve of diagnosis was drawn to distinguish tumor tissue from normal tissue in ccRCC patients. (B) The time-dependent survival ROC curve was drawn to predict the 1-, 3- and 5-year survival rates of ccRCC. (C) A nomogram model integrating key clinicopathologic factors and *PANK1* expression levels to predict survival probability at 1, 3 and 5 years. TPR, true positive rate; FPR, false positive rate; AUC, area under curve; CI, confidence interval; ccRCC, clear cell renal cell carcinoma; ROC, receiver operator characteristic curve.




Figure 5 DNA methylation levels of *PANK1* and its prognostic value in ccRCC. (A) Promoter methylation levels of *PANK1* in normal tissues and primary ccRCC tissues in the UALCAN database. (B-F) Promoter methylation levels of *PANK1* in ccRCC cancer tissues in relation to tumor stage (B), tumor grade (C), nodal metastasis status (D), age (E), and gender (F) by the UALCAN database. (G) The heat map of DNA methylation at the CpG sites in the *PANK1* gene by the MethSurv database. TCGA, The Cancer Genome Atlas; KIRC, Kidney Renal Clear Cell Carcinoma; ccRCC, clear cell renal cell carcinoma; UALCAN, University of Alabama Cancer Database; CpG, Cytosine-phosphate-Guanine.

Table 2 The significant prognostic values of CpG in *PANK1*

Gene symbol	CpG name	HR (95% CI)	LR test P value	UCSC ref gene group	Relation to UCSC CpG Island
<i>PANK1</i>	cg00461642	0.643 (0.401, 1.032)	0.067	Body	N_Shore
	cg03539850	1.396 (0.945, 2.064)	0.094	TSS1500	N_Shore
	cg06326839	0.372 (0.232, 0.596)	0.000039	TSS1500	Island
	cg07134367	1.287 (0.797, 2.077)	0.3	TSS1500	Island
	cg09161592	0.485 (0.308, 0.764)	0.0018	TSS1500	Island
	cg09747456	2.56 (1.727, 3.794)	0.0000028	TSS200	S_Shore
	cg12226046	1.791 (1.078, 2.977)	0.025	Body	N_Shore
	cg14967972	1.263 (0.86, 1.856)	0.23	TSS200	S_Shore
	cg17051995	0.485 (0.276, 0.853)	0.012	3'UTR	Open_Sea
	cg18222926	2.186 (1.46, 3.275)	0.00015	Body	Open_Sea
	cg19519331	1.752 (1.181, 2.598)	0.0053	5'UTR	N_Shore
	cg19953263	0.902 (0.575, 1.416)	0.66	TSS200	S_Shore
	cg20349567	2.113 (1.418, 3.148)	0.00024	TSS200	S_Shore
	cg26739829	1.862 (1.12, 3.094)	0.016	TSS1500	S_Shore

CpG, Cytosine-phosphate-Guanine; *PANK1*, pantothenate kinase-1; HR, hazard ratio; CI, confidence interval; LR, likelihood-ratio; UCSC, University of California Santa Cruz; TSS, transcription initiation site; UTR, untranslated region.

carcinogenic mechanism of *PANK1* (see *Figure 6B*). In this study, *PANK1*-binding proteins were investigated using the STRING network, and the results showed that *PANK1* interacts with ion channels, including the epidermal growth factor receptor (EGFR) pathway-, energy homeostasis-, and endocytosis-related proteins (see *Figure 6C*).

PANK1 is significantly correlated with tumor-infiltrating immune cells in ccRCC

We further examined whether *PANK1* expression was associated with the levels of immune cell infiltration in ccRCC. The single-sample gene set enrichment analysis tool from R and the Spearman's R value were used to investigate the potential associations between the *PANK1* expression and infiltration levels of 24 immune cell types. *PANK1* expression was found to be significantly correlated with B cells, cytotoxic cells, DCs, eosinophils, macrophages, neutrophils, natural killer (NK) cells, T helper cells, Th1 cells, follicular helper T (TFH) cells, and Treg cells (see *Figure 7A, 7B*). We also found that high levels of B cells and low levels of eosinophils were associated with the poor prognosis of ccRCC patients ($P < 0.05$; see *Figure 7C*). Further research showed that *PANK1* expression was positively correlated with the infiltration levels

of T helper cells ($r = 0.092$, $P = 0.032$), eosinophils ($r = 0.310$, $P < 0.001$), and neutrophils ($r = 0.333$, $P < 0.001$). Conversely, *PANK1* expression was negatively correlated with B cells ($r = -0.181$, $P < 0.001$), cytotoxic cells ($r = -0.219$, $P < 0.001$), Tregs ($r = -0.386$, $P < 0.001$), TFH cells ($r = -0.096$, $P = 0.026$), DCs ($r = -0.132$, $P = 0.002$), macrophages ($r = -0.159$, $P < 0.001$), and NK cells ($r = -0.106$, $P = 0.014$; see *Figure 7D*). Next, the relationship between *PANK1* expression and immune infiltration was investigated. Somewhat surprisingly, we found significant differences in the levels of infiltrating immune cells, including B cells, cytotoxic cells, Tregs, TFH cells, DCs, macrophages, NK cells, eosinophils, and neutrophils ($P < 0.05$) when *PANK1* expression was categorized into high and low groups (see *Figure 7E*). These results indicated that *PANK1* participates in immune cell infiltration in ccRCC.

Effects of PANK1 on the biological features of ccRCC cells

To analyze the effects of *PANK1* on the biological features of ccRCC, 2 cell lines (i.e., 786-O and CaKi-2) were used for further experiments. We found that the knockdown of *PANK1* promoted cell proliferation in both the 786-O and CaKi-2 cells (see *Figure 8A*). Additionally, the OCR values of these 2 cell lines were measured, and the results




Figure 6 Function and pathway enrichment analyses of PANK1 in ccRCC. (A) Significant GO terms (including BP, MF, and CC) of the top 100 genes most associated with PANK1. (B) Significant KEGG pathways of the top 100 genes most associated with PANK1. (C) PANK1-binding proteins obtained by the STRING tool. BP, biological process; CC, cellular composition; MF, molecular function; ccRCC, clear cell renal cell carcinoma; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.

revealed that *PANK1*-specific siRNA (siPANK1) increased the OCR and mitochondrial-specific ROS production (see *Figure 8B,8C*). These results indicate that *PANK1* regulates ccRCC pathogenesis by modulating the global metabolism of tumor cells.

Discussion

CcRCC is a type of severe malignant tumor and has increased in incidence in recent years (1). Great advances in the understanding the molecular mechanisms of ccRCC




Figure 7 Correlations between PANK1 expression and immune cell infiltration of ccRCC. (A) Lollipop chart of PANK1 expression level in 24 immune cells. (B) Immune cell infiltration significantly associated with PANK1 expression. (C) Effect of immune cell infiltration on prognosis in ccRCC patients. Comparison of the clinical survival outcomes of ccRCC patients in the high and low B cells/eosinophils groups. (D) Correlation between PANK1 expression and immune cell infiltration. Correlation between PANK1 expression and the immune infiltration of B cells, T helper cells, cytotoxic cells, Treg, TFH, DC, macrophages, NK, eosinophils, and neutrophils cells. TPM, transcripts per million. (E) Comparison of immune cells between high- and low-PANK1 expression groups. Histogram showing the difference among B cells, T helper cells, cytotoxic cells, Treg, TFH, DC, macrophages, NK, eosinophils, neutrophils cells infiltration levels between the high- and low-PANK1 expression groups. *P<0.05, **P<0.01, ***P<0.001, ns, not significant. ccRCC, clear cell renal cell carcinoma; Th17, T helper-17; Tem, central memory T cell; iDC, immature dendritic cells; TFH, follicular helper T cells; NK, natural killer; Tem, effector memory T cells; aDC, activated DC; pDC, plasmacytoid DC; Treg, Regulatory T cells.




Figure 8 The effects of *PANK1* on the cell viability and mitochondrial functions of ccRCC cells. (A) Cell viability assays of *siPANK1* compared to *siNC* in 786-O and CaKi-2 cells for 5 days. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. (B) Representative mitochondrial OCR curves of ccRCC cells upon *siNC* and *siPANK1*. (C) Mitochondrial-specific ROS productions in both 786-O and CaKi-2 cells upon *siNC* and *siPANK1*. ** $P < 0.01$. Dig, digitonin; G+M, glutamate and malate; ADP, adenosine diphosphate; SUC, succinate; FCCP, one of the key uncoupling agents; ROT, rotenone; *siNC*, siRNA negative control; ccRCC, clear cell renal cell carcinoma; OCR, oxygen consumption rate; ROS, reactive oxygen species.

pathogenesis and progression have led to unprecedented progress in the diagnosis of and therapeutic strategies for ccRCC (31). Developments have been made in the treatment of ccRCC, including surgical resection, molecular-targeted drugs (vascular endothelial growth factor, platelet-derived growth factor, EGFR, and mTOR), and immunotherapies targeting the programmed death-ligand 1/programmed

death-1 pathway in advanced ccRCC (32). However, the therapeutic effects are still unsatisfactory, and as ccRCC is a heterogeneous disease, more research needs to be conducted to identify novel targets to enable the better diagnosis, therapy, and prognosis of ccRCC.

In this study, we mainly focused on *PANK1*, an enzyme critical in the regulation of global metabolism, whose role

in ccRCC and other tumors is still unknown. Using TCGA and GEO databases, we confirmed that *PANK1* expression is more decreased in ccRCC tissues than normal renal tissues. Promoter methylation status may contribute to this expression discrepancy. We also found that *PANK1* expression was significantly correlated with TNM stage, pathological stage, histological grade, and survival status. Additionally, its expression was correlated with the immune infiltration status of several crucial immune cell types. Thus, *PANK1* expression was shown to have a good ability to distinguish between tumor tissues and normal tissues.

A pan-cancer analysis showed that *PANK1* was downregulated in all types of renal cancers. Further research revealed that low *PANK1* levels were associated with reduced OS, DSS, and PFS in ccRCC patients. The logistic regression demonstrated that *PANK1* expression level was correlated with the clinicopathological characteristics of ccRCC. Additionally, the univariate and multivariate Cox analyses indicated that *PANK1* was an independent positive factor for predicting clinical prognosis. These data and the results of the ROC analysis suggested that *PANK1* may be a promising prognostic biomarker for ccRCC patients. Further, while gene mutations are closely related to tumor pathogenesis and are often associated with a bad prognosis, the percentage of *PANK1* genetic alterations in ccRCC was only approximately 0.5% (cBioPortal, www.cbioportal.org; data not provided). Additionally, changes in DNA methylation status are common epigenetic mechanisms in almost all forms of cancer. The relationship between the DNA methylation levels of *PANK1* and the prognosis of ccRCC patients was investigated, and we found that promoter methylation was associated with the pathological stage and histological grade. The hypermethylation of 9 CpG sites was correlated with a worse OS, and contributed to decreased *PANK1* expression levels in ccRCC patients, especially among those with a poor prognosis.

The tumor microenvironment (TME) is composed of various types of immune cells in tumor and plays an important role in tumor progression, metastasis, and treatment response (33). The composition of tumor-infiltrating immune cells strongly affects the TME, tumor behavior, and clinical prognosis. As *PANK1* is a critical gene in cell metabolism regulation, we hypothesized that *PANK1* affects the TME by modulating the proportions and infiltration of specific immune cell types. A recent study showed that *PANK1* is associated with immune cell infiltration (16). In the present study, we systematically

analyzed the effects of *PANK1* on immune cell infiltration, and found that Tregs, cytotoxic cells, B cells, macrophages, DCs, NK cells, and TFH cells were negatively correlated with *PANK1* expression, while neutrophils, eosinophils, and T helper cells were positively correlated with *PANK1* expression. More importantly, high *PANK1*-expressing or low *PANK1*-expressing tumors had aberrant patterns of immune cell infiltration rates. Certainly, the regulation of the TME is highly of complex, and the proportions of immune cell types in the TME may also affect tumor cell survival. Future studies need to be conducted to further explore the relationship between *PANK1* and these different cell types.

To determine the BPs in which *PANK1* is involved, a functional analysis was conducted using GO/KEGG and STRING. Consistent with the function of *PANK1* as a critical gene in global metabolism regulation, we found that most *PANK1*-related genes were associated with coenzyme binding, the mitochondrial matrix, peroxisome, and fatty acid metabolism, and may also be related to carcinogenesis. A previous study indicated that *PANK1* is a crucial rate-limiting enzyme in the *de-novo* synthesis of CoA, which controls the ratio and rate of CoA to acetyl-CoA. The systemic knockout of *PANK1* and *PANK2* in neurons results in a decrease in the content of short-chain acyl-CoA (14). In *Lep*-knockout mice, the knockout of *Pank1* alleviated the hyperglycemia and hyperinsulinemia phenotypes (34). Leonardi *et al.* demonstrated the importance of *PANK1* during fasting, which supports the metabolic transition from glucose use and fatty acid synthesis to gluconeogenesis and fatty acid oxidation, and suggests that *PANK1* could be a therapeutic target for metabolic disorders (35).

Additionally, as *PANK1* is considered an important downstream target of p53 transcription (13,15,36), its role in carcinogenesis has been investigated in recent years. *PANK* genes have been shown to have prognostic significance in acute myeloid leukemia using TCGA database (37). A recent study revealed that the overexpression of *PANK1* inhibits the proliferation, growth, invasion, and tumorigenicity of hepatocellular carcinoma cells by inhibiting Wnt/ β -catenin signaling (11). However, the role of *PANK1* in other tumors has not yet been investigated. In our study, we found that *PANK1* was significantly associated with clinical prognosis, and *PANK1* knockdown promoted cell proliferation in ccRCC.

The role of energy metabolism has been shown to play dominant roles in both cancer pathogenesis and

progression. Findings that metabolic demands change frequently during tumor initiation, progression, and metastasis have challenged our understanding of tumor biology and the development of novel therapeutics. Thus, investigating the role of TME cells in the remodeling of cancer cell energy metabolism has become an increasingly important area of research (38). Additionally, metabolic changes have been shown to occur in ccRCC. Notably, Wu *et al.* reported that redox-related genes were associated with immune infiltration and could accurately predict ccRCC prognosis (39). Xing *et al.* identified 10 glycolysis-related genes that predicted OS for ccRCC patients (40). In the present study, we found that *PANK1* knockdown regulated mitochondrial bioenergetics and redox status, which is a critical mechanism underlying *PANK1*-mediated effects on ccRCC. Tumor-associated immune cells and immune checkpoint inhibition play important roles in the carcinogenesis and treatment of ccRCC (41). *PANK1* has been shown to be correlated with the infiltration status of several types of immune cells. Thus, *PANK1* may be an important link between metabolism and immunity during cancer pathogenesis and treatment.

This study was the first to systematically explore the relationship between *PANK1* expression and ccRCC; however, it had some limitations. First, most of the clinical and expression data analyzed by bioinformatics were downloaded from TCGA or GEO databases, and our findings require further validation by systematical experimental investigations. Second, the immune infiltration status regulated by *PANK1* requires further experimental exploration. Third, longer follow-up durations and larger cohorts of patients are needed to validate that *PANK1* is an accurate prognosis predictor.

Conclusions

In this study, we verified for the first time the value of *PANK1* in the prognosis prediction of ccRCC. The DNA methylation of *PANK1* is related to the prognosis of ccRCC. *PANK1* not only participates in the occurrence and progression of ccRCC but also its immune regulation. Additionally, *PANK1* associates with mitochondrial metabolism and may be an important link between tumor metabolism and immunity. Thus, *PANK1* could be a potential prognostic biomarker and a promising therapeutic target for ccRCC. Further mechanistic studies need to be conducted to validate our findings and promote its clinical

application.

Acknowledgments

We would like to thank H. Nikki March, PhD, from Liwen Bianji (Edanz) (www.liwenbianji.cn/), for editing the English text of a draft of this manuscript.

Funding: This study was funded by the Specialized Scientific Program of the Innovation Platform for Academicians of Hainan Province (YSPTZX202026), the Hainan Provincial Natural Science Foundation of China (821QN383), the Specialized Scientific Research Project of Military Health Care (21BJZ37), the NSFC General Project (81570679), Beijing NOVA program (Z161100004916141), and the Innovation Platform for Academicians of Hainan Province (Academician Chen Xiangmei of Hainan Province Kidney Diseases Team Innovation Center).

Footnote

Reporting Checklist: The authors have completed the TRIPOD reporting checklist. Available at <https://tcr.amegroups.com/article/view/10.21037/tcr-22-1488/rc>

Data Sharing Statement: Available at <https://tcr.amegroups.com/article/view/10.21037/tcr-22-1488/dss>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://tcr.amegroups.com/article/view/10.21037/tcr-22-1488/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work, including ensuring that any questions related to the accuracy or integrity of any part of the work have been appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license).

See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. *CA Cancer J Clin* 2022;72:7-33.
2. Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. *J Clin Oncol* 2017;35:591-7.
3. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med* 2019;380:1103-15.
4. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med* 2019;380:1116-27.
5. Wu Y, Zhang X, Wei X, et al. A Mitochondrial Dysfunction and Oxidative Stress Pathway-Based Prognostic Signature for Clear Cell Renal Cell Carcinoma. *Oxid Med Cell Longev* 2021;2021:9939331.
6. Yao Z, Zheng Z, Zheng X, et al. Comprehensive Characterization of Metabolism-Associated Subtypes of Renal Cell Carcinoma to Aid Clinical Therapy. *Oxid Med Cell Longev* 2022;2022:9039732.
7. Farber NJ, Kim CJ, Modi PK, et al. Renal cell carcinoma: the search for a reliable biomarker. *Transl Cancer Res* 2017;6:620-32.
8. Petitprez F, Ayadi M, de Reyniès A, et al. Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. *Front Oncol* 2021;11:643065.
9. Qi X, Li Q, Che X, et al. The Uniqueness of Clear Cell Renal Cell Carcinoma: Summary of the Process and Abnormality of Glucose Metabolism and Lipid Metabolism in ccRCC. *Front Oncol* 2021;11:727778.
10. Chen C, Zhao W, Lu X, et al. AUP1 regulates lipid metabolism and induces lipid accumulation to accelerate the progression of renal clear cell carcinoma. *Cancer Sci* 2022. [Epub ahead of print].
11. Zi Y, Gao J, Wang C, et al. Pantothenate Kinase 1 Inhibits the Progression of Hepatocellular Carcinoma by Negatively Regulating Wnt/ β -catenin Signaling. *Int J Biol Sci* 2022;18:1539-54.
12. Czumaj A, Szrok-Jurga S, Hebanowska A, et al. The Pathophysiological Role of CoA. *Int J Mol Sci* 2020;21:9057.
13. Wang SJ, Yu G, Jiang L, et al. p53-Dependent regulation of metabolic function through transcriptional activation of pantothenate kinase-1 gene. *Cell Cycle* 2013;12:753-61.
14. Subramanian C, Yao J, Frank MW, et al. A pantothenate kinase-deficient mouse model reveals a gene expression program associated with brain coenzyme A reduction. *Biochim Biophys Acta Mol Basis Dis* 2020;1866:165663.
15. Böhlig L, Friedrich M, Engeland K. p53 activates the PANK1/miRNA-107 gene leading to downregulation of CDK6 and p130 cell cycle proteins. *Nucleic Acids Res* 2011;39:440-53.
16. Zhang Y, Tang M, Guo Q, et al. The value of erlotinib related target molecules in kidney renal cell carcinoma via bioinformatics analysis. *Gene* 2022;816:146173.
17. Zhao K, Ma Z, Zhang W. Comprehensive Analysis to Identify SPP1 as a Prognostic Biomarker in Cervical Cancer. *Front Genet* 2022;12:732822.
18. Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res* 2017;45:W98-W102.
19. Chen J, Wang H, Zhou L, et al. A combination of circulating tumor cells and CA199 improves the diagnosis of pancreatic cancer. *J Clin Lab Anal* 2022;36:e24341.
20. Shang BB, Chen J, Wang ZG, et al. Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma. *PeerJ* 2021;9:e12315.
21. Zhou Q, Hou Z, Zuo S, et al. LUCAT1 promotes colorectal cancer tumorigenesis by targeting the ribosomal protein L40-MDM2-p53 pathway through binding with UBA52. *Cancer Sci* 2019;110:1194-207.
22. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res* 2019;47:D607-13.
23. Modhukur V, Iljasenko T, Metsalu T, et al. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. *Epigenomics* 2018;10:277-88.
24. Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. *Nat Biotechnol* 2020;38:675-8.
25. Li T, Fan J, Wang B, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. *Cancer Res* 2017;77:e108-10.
26. Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. *Nat Methods* 2015;12:453-7.
27. Wang B, Ni Z, Dai X, et al. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells. *Mol Cancer* 2014;13:98.

28. Wang B, Xiong S, Lin S, et al. Enhanced Mitochondrial Transient Receptor Potential Channel, Canonical Type 3-Mediated Calcium Handling in the Vasculature From Hypertensive Rats. *J Am Heart Assoc* 2017;6:005812.
29. Ma B, Wang P. PANK1 is a Prognostic Biomarker Associated with Immune Infiltration of Clear Cell Renal Carcinoma. Research Square. [Preprint.] Oct 13, 2021 [accessed 2022 June 6]. Available online: <https://doi.org/10.21203/rs.3.rs-957747/v1>.
30. Cui Y, Zhou Z, Chai Y, et al. Upregulated GSDMB in Clear Cell Renal Cell Carcinoma Is Associated with Immune Infiltrates and Poor Prognosis. *J Immunol Res* 2021;2021:7753553.
31. Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. *Science* 2018;359:801-6.
32. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med* 2002;8:793-800.
33. Kim MC, Jin Z, Kolb R, et al. Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. *Cancers (Basel)* 2021;13:5856.
34. Leonardi R, Rock CO, Jackowski S. Pank1 deletion in leptin-deficient mice reduces hyperglycaemia and hyperinsulinaemia and modifies global metabolism without affecting insulin resistance. *Diabetologia* 2014;57:1466-75.
35. Leonardi R, Rehg JE, Rock CO, et al. Pantothenate kinase 1 is required to support the metabolic transition from the fed to the fasted state. *PLoS One* 2010;5:e11107.
36. Yang L, Zhang B, Wang X, et al. P53/PANK1/miR-107 signalling pathway spans the gap between metabolic reprogramming and insulin resistance induced by high-fat diet. *J Cell Mol Med* 2020;24:3611-24.
37. Liu Y, Cheng Z, Li Q, et al. Prognostic significance of the PANK family expression in acute myeloid leukemia. *Ann Transl Med* 2019;7:261.
38. Herst PM, Carson GM, Eccles DA, et al. Bioenergetic and Metabolic Adaptation in Tumor Progression and Metastasis. *Front Oncol* 2022;12:857686.
39. Wu Y, Wei X, Feng H, et al. Integrated Analysis to Identify a Redox-Related Prognostic Signature for Clear Cell Renal Cell Carcinoma. *Oxid Med Cell Longev* 2021;2021:6648093.
40. Xing Q, Zeng T, Liu S, et al. A novel 10 glycolysis-related genes signature could predict overall survival for clear cell renal cell carcinoma. *BMC Cancer* 2021;21:381.
41. Zarrabi K, Walzer E, Zibelman M. Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities. *Cancers (Basel)* 2021;13:3652.

(English Language Editor: L. Huleatt)

Cite this article as: Wang B, Liu B, Luo Q, Sun D, Li H, Zhang J, Jin X, Cheng X, Niu J, Yuan Q, Chen Y. *PANK1* associates with cancer metabolism and immune infiltration in clear cell renal cell carcinoma: a retrospective prognostic study based on the TCGA database. *Transl Cancer Res* 2022;11(7): 2321-2337. doi: 10.21037/tcr-22-1488